150mg Erlotinib Tablets IP

150mg Erlotinib Tablets IP Specification

Packaging Type
Box

Brand Name
Erlotero 150

Dosage Form
Film-coated tablet

Origin of Medicine
India

Salt Composition
Erlotinib Hydrochloride 150mg

Indication
Indicated for the treatment of locally advanced or metastatic NSCLC and in combination with gemcitabine for pancreatic cancer

Life Span
24 months from manufacture date

Pacakaging (Quantity Per Box)
30 tablets per box

Drug Type
Allopathic, Prescription only

Ingredients
Erlotinib Hydrochloride

Physical Form
Tablets, Tablets

Function
Antineoplastic (anti-cancer), Anticancer / Antineoplastic Agent

Recommended For
Non-small cell lung cancer (NSCLC), Pancreatic cancer

Dosage
As directed by the oncologist

Dosage Guidelines
Take orally, do not crush or chew, follow medical prescription

Suitable For
Adults, Adults

Quantity
30 tablets

Storage Instructions
Store below 30C, protect from moisture and light

MRP
As per label

Therapeutic Class
Tyrosine kinase inhibitor

Color
White to off-white

Side Effects
Rash, diarrhea, loss of appetite, fatigue

Contraindications
Known hypersensitivity to Erlotinib or any excipients

Shape
Oval, film-coated tablets

Route of Administration
Oral

Prescription Requirement
Yes

150mg Erlotinib Tablets IP Trade Information

Minimum Order Quantity
10 Boxes

Payment Terms
Cash Against Delivery (CAD), Cash on Delivery (COD), Cash in Advance (CID)

Supply Ability
100 Boxes Per Month

Delivery Time
5-7 Days

Main Domestic Market
All India

About 150mg Erlotinib Tablets IP

Grab the phenomenal Erlotero 150 (Erlotinib Tablets IP 150mg) before our special offer is ending soon! Enjoy best-in-class treatment with these first-rate, white to off-white oval, film-coated tablets crafted for adults. Indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) and, in combination with gemcitabine, for pancreatic cancer, Erlotero 150 is an antineoplastic agent that requires a prescription. Each box contains 30 tablets, and should be stored below 30C, away from moisture and light. Dosage is as prescribed by an oncologist. Don't miss this opportunity!

Targeted Therapy with Erlotinib 150mg Tablets

Erlotero 150 provides specialized support for adult patients diagnosed with non-small cell lung cancer (NSCLC) and pancreatic cancer. Designed for oral application, its film-coated tablets ensure convenient administration without crushing or chewing. This medication functions effectively as an anticancer agent, inhibiting tyrosine kinases in cancer cells. Ideally suited for clinical, hospital, and home-based treatment under oncologist supervision, it helps control cancer progression in specific advanced cases.

Trusted Export and Professional Packaging

Our Erlotero 150 is expertly handled and valued during international transactions, with a prime focus on main export markets across Asia, Africa, and Latin America. Shipments are carefully handed over at major Indian FOB ports, ensuring secure and timely delivery. The product is packaged in boxes, each containing 30 tablets, providing excellent protection during freight and storage, while upholding stringent quality assurance for global clients.

FAQ's of 150mg Erlotinib Tablets IP:

Q: How should I take Erlotero 150mg Tablets?

A: Erlotero 150mg Tablets must be taken orally with water, exactly as directed by your oncologist. Do not crush or chew the film-coated tablets to ensure proper efficacy.

Q: What cancers are Erlotero 150mg Tablets indicated for?

A: These tablets are primarily indicated for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) as well as, in combination with gemcitabine, for pancreatic cancer.

Q: When should patients avoid Erlotero 150?

A: Patients with known hypersensitivity to Erlotinib or any of its excipients should not use Erlotero 150. Consult your doctor for alternative options if you have allergies to its ingredients.

Q: Where can Erlotero 150mg Tablets be administered?

A: Erlotero 150 is suitable for administration in hospitals, clinics, or even at home, provided it is under strict supervision and upon an oncologist's recommendation.